HRP20161556T1 - Virusna čestica otpuštena nakon infekcije sisavačkih stanica ljudskim citomegalovirusom (hcmv) koji sadrži fuzijski protein i njezina upotreba - Google Patents
Virusna čestica otpuštena nakon infekcije sisavačkih stanica ljudskim citomegalovirusom (hcmv) koji sadrži fuzijski protein i njezina upotreba Download PDFInfo
- Publication number
- HRP20161556T1 HRP20161556T1 HRP20161556TT HRP20161556T HRP20161556T1 HR P20161556 T1 HRP20161556 T1 HR P20161556T1 HR P20161556T T HRP20161556T T HR P20161556TT HR P20161556 T HRP20161556 T HR P20161556T HR P20161556 T1 HRP20161556 T1 HR P20161556T1
- Authority
- HR
- Croatia
- Prior art keywords
- viral particle
- particle according
- hcmv
- heterologous peptide
- viral
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims 38
- 230000003612 virological effect Effects 0.000 title claims 33
- 241000701024 Human betaherpesvirus 5 Species 0.000 title claims 18
- 108020001507 fusion proteins Proteins 0.000 title claims 4
- 102000037865 fusion proteins Human genes 0.000 title claims 4
- 208000015181 infectious disease Diseases 0.000 title claims 3
- 210000004962 mammalian cell Anatomy 0.000 title claims 2
- 230000000890 antigenic effect Effects 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 102000003886 Glycoproteins Human genes 0.000 claims 10
- 108090000288 Glycoproteins Proteins 0.000 claims 10
- 230000000694 effects Effects 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 244000052637 human pathogen Species 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 229960005486 vaccine Drugs 0.000 claims 4
- 230000006806 disease prevention Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000003472 neutralizing effect Effects 0.000 claims 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 108020005202 Viral DNA Proteins 0.000 claims 1
- 210000000234 capsid Anatomy 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16161—Methods of inactivation or attenuation
- C12N2710/16162—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (30)
1. Virusna čestica otpuštena nakon infekcija sisavačkih stanica ljudskim citomegalovirusom (HCMV), gdje virusna čestica je gusto tijelo, naznačena time što
a) čestica je okružena lipidnom membranom, u koju su uklopljeni virusni glikoproteini;
b) čestica ne sadrži ni virusnu DNA niti kapside; i
c) čestica sadrži fuzijski protein koji sadrži jedan ili više dijelova T-staničnog antigena pp65 i najmanje jedan antigeni heterologni peptid;
te što je najmanje jedan antigeni heterologni peptid insertiran na aminokiselinskom položaju W175 ili A534 u aminokiselinskom slijedu T-staničnog antigena pp65 sa SEQ ID NO: 1.
2. Virusna čestica u skladu s patentnim zahtjevom 1, naznačena time što je najmanje jedan antigeni heterologni peptid insertiran na aminokiselinskom položaju W175 u aminokiselinskom slijedu T-staničnog antigena pp65.
3. Virusna čestica u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačena time što aminokiselinski slijed T-staničnog antigena pp65 sadrži aminokiselinski slijed u skladu s SEQ ID NO: 1.
4. Virusna čestica u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je čestica visoko antigena.
5. Virusna čestica u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačena time što čestica može inducirati pojavu neutralizirajućih protutijela.
6. Virusna čestica u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time što čestica može inducirati CD8+ T limfocitni odgovor.
7. Virusna čestica u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačena time što je najmanje jedan antigeni heterologni peptid antigen predočen MHC-klasom I.
8. Virusna čestica u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačena time što najmanje jedan antigeni heterologni peptid sadrži ili sačinjen od jednog ili više dijelova jednog ili više proteina koji se razlikuju od pp65.
9. Virusna čestica u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačena time što najmanje jedan antigeni heterologni peptid sadrži ili je jedan ili više dijelova HCMV glikoproteina.
10. Virusna čestica u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačena time što najmanje jedan antigeni heterologni peptid sadrži ili je jedan ili više dijelova HCMV glikoproteina gB.
11. Virusna čestica u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačena time što najmanje jedan antigeni heterologni peptid sadrži ili je jedan ili više dijelova HCMV glikoproteina gH.
12. Virusna čestica u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačena time što najmanje jedan antigeni heterologni peptid sadrži ili se sastoji od najmanje dva HCMV glikoproteina koji su varijante određenog glikoproteina iz različitih sojeva HCMV.
13. Virusna čestica u skladu s patentnim zahtjevom 12, naznačena time što jedna od najmanje dvije varijante određenog glikoproteina je varijanta HCMV soja Towne, a druga od najmanje dvije varijante određenog glikoproteina je varijanta HCMV soja Ad169.
14. Virusna čestica u skladu s bilo kojim od patentnih zahtjeva 12 do 13, naznačena time što je glikoprotein gB protein iz HCMV.
15. Virusna čestica u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačena time što najmanje jedan antigeni heterologni peptid sadrži ili je jedan ili više dijelova HCMV proteina IE1.
16. Virusna čestica u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačena time što najmanje jedan antigeni heterologni peptid sadrži ili je jedan ili više dijelova HCMV glikoproteina i jedan ili više dijelova HCMV proteina IE1.
17. Virusna čestica u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačena time što je najmanje jedan antigeni heterologni peptid jedan ili više dijelova proteina koji je dio ljudskog patogena koji nije HCMV.
18. Virusna čestica u skladu s patentnim zahtjevom 17, naznačena time što je protein koji je dio ljudskog patogena koji nije HCMV protein protiv kojeg se pojavljuju citotoksični T limfociti kod ljudi prilikom prirodne infekcije ljudi ljudskim patogenom koji nije HCMV.
19. Virusna čestica u skladu s patentnim zahtjevom 18, naznačena time što ljudski patogen koji nije HCMV je ljudski patogen kojeg se bira iz skupine koju čine HIV-1, HBV, HCV i influenca.
20. Virusna čestica u skladu s bilo kojim od patentnih zahtjeva 1 do 19, naznačena time što je fuzijski protein fuzijski protein koji sadrži T-stanični antigen pp65 pune duljine i najmanje jedan antigeni heterologni peptid.
21. Virusna čestica u skladu s bilo kojim od patentnih zahtjeva 1 do 20, ili više njih, naznačena time što je namijenjena proizvodnji medikamenta za liječenje i/ili sprječavanje bolesti.
22. Virusna čestica u skladu s bilo kojim od patentnih zahtjeva 1 do 20, ili više njih, naznačena time što je namijenjena upotrebu u postupku liječenja i/ili sprječavanja bolesti.
23. Virusna čestica u skladu s bilo kojim od patentnih zahtjeva 21 do 22, naznačena time što je bolest bolest koja se može liječiti i/ili spriječiti pojavom neutralizirajućih protutijela protiv najmanje jednog antigenog heterolognog peptida ili njegovog derivata, ili indukcijom CD8+ T limfocitnog odgovora protiv najmanje jednog antigenog heterolognog peptida ili njegovog derivata.
24. Virusna čestica u skladu s bilo kojim od patentnih zahtjeva 1 do 20, ili više njih, naznačena time što je namijenjena proizvodnji cjepiva.
25. Virusna čestica u skladu s patentnim zahtjevom 24, naznačena time što je cjepivo namijenjeno liječenju i/ili sprječavanju infekcije HCMV-om.
26. Virusna čestica u skladu s patentnim zahtjevom 24, naznačena time što je cjepivo namijenjeno liječenju i/ili sprječavanju nuspojava presađivanja.
27. Virusna čestica u skladu s patentnim zahtjevom 26, naznačena time što je presađivanje presađivanje čvrstog organa ili krvotvornih matičnih stanica.
28. Virusna čestica u skladu s bilo kojim od patentnih zahtjeva 26 do 27, naznačena time što je nuspojava posljedica ili prati infekciju HCMV-om.
29. Upotreba virusne čestice u skladu s bilo kojim od patentnih zahtjeva 1 do 20, naznačena time što je namijenjena proizvodnji medikamenta za liječenje i/ili sprječavanje bolesti ili nuspojava, gdje bolest ili nuspojave je bolest ili su nuspojave kao što su definirane u bilo kojem od prethodnih patentnih zahtjeva.
30. Upotreba virusne čestice u skladu s bilo kojim od patentnih zahtjeva 1 do 20, naznačena time što je namijenjena proizvodnji cjepiva za liječenje i/ili sprječavanje bolesti ili nuspojave, gdje bolest ili nuspojave je bolest ili su nuspojave kao što su definirane u bilo kojem od prethodnih patentnih zahtjeva.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10003712 | 2010-04-06 | ||
| PCT/EP2011/001712 WO2011124371A1 (en) | 2010-04-06 | 2011-04-06 | Viral particle released after infection of mammalian cells by human cytomegalovirus (hcmv) containing a fusion protein and use thereof |
| EP11713689.5A EP2556150B1 (en) | 2010-04-06 | 2011-04-06 | Viral particle released after infection of mammalian cells by human cytomegalovirus (hcmv) containing a fusion protein and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161556T1 true HRP20161556T1 (hr) | 2016-12-30 |
Family
ID=43923731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161556TT HRP20161556T1 (hr) | 2010-04-06 | 2016-11-22 | Virusna čestica otpuštena nakon infekcije sisavačkih stanica ljudskim citomegalovirusom (hcmv) koji sadrži fuzijski protein i njezina upotreba |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9486517B2 (hr) |
| EP (1) | EP2556150B1 (hr) |
| JP (1) | JP5827312B2 (hr) |
| KR (2) | KR101839535B1 (hr) |
| CN (1) | CN102933706B (hr) |
| AU (1) | AU2011238085B2 (hr) |
| BR (1) | BR112012025392B1 (hr) |
| CA (1) | CA2795346C (hr) |
| CY (1) | CY1118138T1 (hr) |
| DK (1) | DK2556150T3 (hr) |
| ES (1) | ES2601850T3 (hr) |
| HR (1) | HRP20161556T1 (hr) |
| HU (1) | HUE030704T2 (hr) |
| IL (1) | IL222229A (hr) |
| LT (1) | LT2556150T (hr) |
| MX (1) | MX2012011639A (hr) |
| MY (1) | MY162335A (hr) |
| PL (1) | PL2556150T3 (hr) |
| PT (1) | PT2556150T (hr) |
| RS (1) | RS55421B1 (hr) |
| RU (1) | RU2623172C2 (hr) |
| SG (2) | SG184261A1 (hr) |
| SI (1) | SI2556150T1 (hr) |
| SM (1) | SMT201700002B (hr) |
| WO (1) | WO2011124371A1 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011101446A1 (de) * | 2011-05-10 | 2012-11-15 | Aicuris Gmbh & Co. Kg | Herstellung von "Dense Bodies" (DB) |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| JP6980780B2 (ja) | 2016-10-21 | 2021-12-15 | モデルナティーエックス， インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
| US20210228711A1 (en) | 2018-06-08 | 2021-07-29 | Vakzine Projekt Management Gmbh | Viral particle - based vaccine |
| EP3587566A1 (en) | 2018-06-29 | 2020-01-01 | Bodo Plachter | Hcmv vaccine strain |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5733540A (en) * | 1995-03-08 | 1998-03-31 | Lee; Peter Poon-Hang | Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria |
| DE19910044A1 (de) * | 1999-03-08 | 2000-09-14 | Bodo Plachter | Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff |
| EP1799255A4 (en) * | 2004-06-25 | 2008-10-01 | Medimmune Vaccines Inc | RECOMBINANT HUMANESE CYTOMEGALOVIRUS AND HETEROLOGIST ANTIGENS CONTAINING VACCINES |
-
2011
- 2011-04-06 SI SI201131016A patent/SI2556150T1/sl unknown
- 2011-04-06 MX MX2012011639A patent/MX2012011639A/es active IP Right Grant
- 2011-04-06 WO PCT/EP2011/001712 patent/WO2011124371A1/en active Application Filing
- 2011-04-06 SG SG2012071189A patent/SG184261A1/en unknown
- 2011-04-06 MY MYPI2012004446A patent/MY162335A/en unknown
- 2011-04-06 PT PT117136895T patent/PT2556150T/pt unknown
- 2011-04-06 DK DK11713689.5T patent/DK2556150T3/en active
- 2011-04-06 EP EP11713689.5A patent/EP2556150B1/en active Active
- 2011-04-06 JP JP2013503035A patent/JP5827312B2/ja active Active
- 2011-04-06 AU AU2011238085A patent/AU2011238085B2/en active Active
- 2011-04-06 HU HUE11713689A patent/HUE030704T2/en unknown
- 2011-04-06 CA CA2795346A patent/CA2795346C/en active Active
- 2011-04-06 KR KR1020127028033A patent/KR101839535B1/ko active IP Right Grant
- 2011-04-06 US US13/639,636 patent/US9486517B2/en active Active
- 2011-04-06 CN CN201180027797.9A patent/CN102933706B/zh active Active
- 2011-04-06 BR BR112012025392-1A patent/BR112012025392B1/pt active IP Right Grant
- 2011-04-06 SG SG10201502271RA patent/SG10201502271RA/en unknown
- 2011-04-06 ES ES11713689.5T patent/ES2601850T3/es active Active
- 2011-04-06 RU RU2012146775A patent/RU2623172C2/ru active
- 2011-04-06 PL PL11713689T patent/PL2556150T3/pl unknown
- 2011-04-06 LT LTEP11713689.5T patent/LT2556150T/lt unknown
- 2011-04-06 RS RS20161007A patent/RS55421B1/sr unknown
- 2011-04-06 KR KR1020177025664A patent/KR20170108167A/ko not_active Application Discontinuation
-
2012
- 2012-09-27 IL IL222229A patent/IL222229A/en active IP Right Grant
-
2016
- 2016-10-25 CY CY20161101076T patent/CY1118138T1/el unknown
- 2016-11-22 HR HRP20161556TT patent/HRP20161556T1/hr unknown
-
2017
- 2017-01-02 SM SM201700002T patent/SMT201700002B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161556T1 (hr) | Virusna čestica otpuštena nakon infekcije sisavačkih stanica ljudskim citomegalovirusom (hcmv) koji sadrži fuzijski protein i njezina upotreba | |
| Chen et al. | Baculovirus as a gene delivery vector: recent understandings of molecular alterations in transduced cells and latest applications | |
| Eliasson et al. | M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection | |
| Bengtsson et al. | Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice | |
| Wang et al. | Hepatic stellate cells, liver innate immunity, and hepatitis C virus | |
| HRP20191111T1 (hr) | Uvjetno replicirajući citomegalovirusi kao cjepivo za cmv | |
| HRP20171213T1 (hr) | Glikoproteinske čestice nalik virusu (vlp) bjesnoće | |
| WO2008103380A3 (en) | Hepatitis b virus compositions and methods of use | |
| HRP20220924T1 (hr) | Imunoterapija zasnovana na pd-l1 | |
| Lafon | Modulation of the immune response in the nervous system by rabies virus | |
| JP2017510262A5 (hr) | ||
| CN101636177A (zh) | 用于禽流感的基于重组改良型痘苗病毒安卡拉(mva)的疫苗 | |
| Valkenburg et al. | Protection by universal influenza vaccine is mediated by memory CD4 T cells | |
| IN2012DN03209A (hr) | ||
| Wu et al. | A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis | |
| HRP20171697T1 (hr) | Varijanta hiv gp-120 | |
| CN102210861A (zh) | 丙型肝炎病毒多表位肽负荷的树突状细胞治疗性疫苗 | |
| Mao et al. | Avian influenza virus directly infects human natural killer cells and inhibits cell activity | |
| JP2010506926A5 (hr) | ||
| Kim et al. | Application of attenuated coxsackievirus B3 as a viral vector system for vaccines and gene therapy | |
| Tang et al. | Lung tissue-resident memory T cells: the gatekeeper to respiratory viral (re)-infection | |
| Szurgot et al. | Self-adjuvanting influenza candidate vaccine presenting epitopes for cell-mediated immunity on a proteinaceous multivalent nanoplatform | |
| Deshpande et al. | Induction of cytotoxic T-lymphocytes specific for bovine herpesvirus-1 by DNA immunization | |
| RU2018103757A (ru) | Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита | |
| JP2012517239A5 (hr) |